Business
Telix to Host Investor Day in New York City on June 11, 2025
MELBOURNE, Australia and INDIANAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it will host an Investor Day on Wednesday, June 11, 2025, in person, in New York City, from 8:30am ET to 12.00pm ET. Institutional investors, analysts and company guests are cordially invited to attend the session, which will focus on the growth opportunities across Telix’s commercial and clinical portfolio of precision medicine and
About this update from Telix Pharmaceuticals Limited
[{"type":"image","alt":"Telix Pharmaceuticals Limited","displaySize":"","headline":null,"caption":"Telix Pharmaceuticals Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":124,"url":"https://media.zenfs.com/en/globenewswire.com/6571dff84dd3c0b75b95cad39425eee7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KLoBa_N8Zvc1hCwyI8J_pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6571dff84dd3c0b75b95cad39425eee7","width":300,"height":124}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and INDIANAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it will host an Investor Day on Wednesday, June 11, 2025, in person, in New York City, from 8:30am ET to 12.00pm ET.","length":282,"tagName":"p"},{"type":"text","content":"Institutional investors, analysts and company guests are cordially invited to attend the session, which will focus on the growth opportunities across Telix’s commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals.","length":251,"tagName":"p"},{"type":"text","content":"Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behrenbruch; Group Chief Medical Officer, Dr. David N. Cade; CEO Therapeutics, Mr. Richard Valeix and CEO Precision Medicine, Mr. Kevin Richardson.","length":268,"tagName":"p"},{"type":"text","content":"Key Opinion Leaders will also provide their perspectives on the clinical utility and opportunity for Telix’s theranostic candidates.","length":132,"tagName":"p"},{"type":"text","content":"Advance registration is required for in person attendance. Please RSVP by sending an email to [email protected].","length":126,"tagName":"p"},{"type":"text","content":"Note: This event is for qualified institutional investors and analysts.","length":71,"tagName":"p"},{"type":"text","content":"About Telix Pharmaceuticals Limited ","length":35,"tagName":"p"},{"type":"text","content":"Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the Unite...